Knoppbio
Pittsburgh, US · Founded 2010 · 2 known investors
Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
Founders & leadership
Knoppbio was founded in 2010 by Thomas V. Petzinger, Jr. and Michael E. Bozik.
TV
Thomas V. Petzinger, Jr.LLC Manager
ME
Michael E. BozikLLC Manager
SD
Steven DworetzkyExecutive
Board
BA
Benjamin A. GomezLLC Manager
JS
GT
Gregory T. HebrankLLC Manager
Investors · 2
Reported raises · per SEC filings
Form D private placements$61.9M disclosed across 6 rounds · 2012–2020
▶$1raisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1raisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KrestonExecutive Officer
- C. David AdairDirector
- James MatherExecutive Officer
- Calman PrussinExecutive Officer
- Steven DworetzkyExecutive Officer
- Stephen E ButtsDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Benjamin A. GomezDirector
- Offering amount
- $1
- Amount sold
- $1
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedOct 2020 · 24 investors · BiotechnologyRule 506(b)
▶$12.6MraisedOct 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin A. GomezDirector
- James MatherExecutive Officer
- Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- C. David AdairDirector
- Stephen E ButtsDirector
- Jeffrey S. McCormickDirector
- Mark KrestonExecutive Officer
- Calman PrussinExecutive Officer
- Steven DworetzkyExecutive Officer
- Michael E. BozikExecutive Officer, Director, Promoter
- Offering amount
- $26M
- Amount sold
- $12.6M
- Sales commissions
- $472.9K
- Proceeds to insiders
- $2.6M
- Placement agents
- Saturn Capital, Inc.
- First sale
- Jun 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$14.9MraisedJun 2020 · 78 investors · BiotechnologyRule 506(b)
▶$14.9MraisedJun 2020 · 78 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin A. GomezDirector
- Calman PrussinExecutive Officer
- James MatherExecutive Officer
- Mark KrestonExecutive Officer
- Thomas V. Petzinger, Jr.Director, Promoter
- Jeffrey S. McCormickDirector
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Steven DworetzkyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $14.9M
- Proceeds to insiders
- $2.5M
- First sale
- Jul 2012
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KrestonExecutive Officer
- James MatherExecutive Officer
- Calman PrussinExecutive Officer
- Steve DworetzkyExecutive Officer
- Benjamin A. GomezDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger, Jr.Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $1M
- Proceeds to insiders
- $520K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedApr 2015 · 20 investors · BiotechnologyRule 506(b)
▶$5.4MraisedApr 2015 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin A. GomezDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Steven DworetzkyExecutive Officer
- Offering amount
- $12.8M
- Amount sold
- $5.4M
- Sales commissions
- $365.2K
- Proceeds to insiders
- $916K
- Placement agents
- Stillpoint Capital, LLC, MIP Global, Inc.
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Knoppbio do?
- Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
- Who founded Knoppbio?
- Knoppbio was founded by Thomas V. Petzinger, Jr., Michael E. Bozik in 2010.
- Who are Knoppbio's investors?
- Knoppbio's investors include Saturn Partners, Solas BioVentures.
- How much funding has Knoppbio raised?
- Knoppbio has disclosed $61.9M raised across 6 rounds.
- Where is Knoppbio headquartered?
- Knoppbio is headquartered in Pittsburgh, US.